Literature DB >> 17113461

The changing management of low-grade astrocytomas and oligodendrogliomas.

Mark Agulnik1, Warren P Mason.   

Abstract

Low-grade gliomas are uncommon primary brain tumors that preferentially affect young to middle-aged adults. Although they are indolent tumors, low-grade gliomas cause considerable and progressive morbidity and are ultimately fatal. Surgery and radiotherapy are the primary therapeutic options for patients with these diseases. Chemotherapy is playing a larger role in the management of patients with low-grade gliomas. Patients with oligodendrogliomas or other low-grade gliomas that harbor a distinct genetic derangement characterized by allelic loss of chromosomes 1p and 19q appear to have a superior prognosis that is due in part to a more predictable and durable response to treatment. For this subset of patients with low-grade gliomas, treatment with initial chemotherapy and deferred radiotherapy is an increasingly attractive therapeutic approach.

Entities:  

Mesh:

Year:  2006        PMID: 17113461     DOI: 10.1016/j.hoc.2006.09.003

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  3 in total

Review 1.  Radiation Therapy Oncology Group 9802: Controversy or Consensus in the Treatment of Newly Diagnosed Low-Grade Glioma?

Authors:  Nadia N Laack; Jann N Sarkaria; Jan C Buckner
Journal:  Semin Radiat Oncol       Date:  2015-02-21       Impact factor: 5.934

2.  Usefulness of ¹¹C-methionine positron emission tomography for treatment-decision making in cases of non-enhancing glioma-like brain lesions.

Authors:  Atsushi Watanabe; Yoshihiro Muragaki; Takashi Maruyama; Jun Shinoda; Yoshikazu Okada
Journal:  J Neurooncol       Date:  2015-11-26       Impact factor: 4.130

3.  Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival.

Authors:  Sean M McBride; Daniel A Perez; Mei-Yin Polley; Scott R Vandenberg; Justin S Smith; Shichun Zheng; Kathleen R Lamborn; John K Wiencke; Susan M Chang; Michael D Prados; Mitchel S Berger; David Stokoe; Daphne A Haas-Kogan
Journal:  J Neurooncol       Date:  2009-08-25       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.